FBLG · FibroBiologics, Inc. · Executive Compensation
$0.92
-0.02 (-2.56%)
At close · Oct 20
Return incl. dividend (before tax)
Going-concern doubt
— flagged Jul 31, 2026
Substantial doubt about the company's ability to continue as a going concern.
“These factors raise substantial doubt about the Company's ability to continue as a going concern for one year from the issuance of the condensed consolidated financial statements. While management has implemented plans to obtain additional funding, these plans are not sufficient to alleviate the substantial doubt about the Company's ability to continue as a going concern.”View the 10-Q filed Jul 31, 2026
Market Cap
$6.29M
Shares
6.66M
Volume · Oct 20
93.32K
Avg daily vol (3M)
209.17K
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| Pete O’Heeron | Chairperson and CEO | $1,066,191 |
| Hamid Khoja | Chief Scientific Officer | $654,070 |
| Ruben A. Garcia | General Counsel | $626,800 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Ruben A. Garcia | General Counsel | $2,752,843 |
| Pete O’Heeron | Chairperson and CEO | $1,805,199 |
| Hamid Khoja | Chief Scientific Officer | $853,646 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Pete O’Heeron | Chairperson and CEO | $4,286,308 |
| Mark Andersen | Chief Financial Officer | $1,329,808 |
| Hamid Khoja | Chief Scientific Officer | $1,307,758 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Pete O’Heeron | Chairperson and CEO | $922,485 |
| Hamid Khoja | Chief Scientific Officer | $497,609 |
| Mark Andersen | Chief Financial Officer | $379,438 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Leigh Steinberg | Class II director of the Board | Appointed | 2026-08-24 |
| Kathleen Rubins, Ph.D. | Class III director | Appointed | 2026-07-09 |
| Matt Link | Board of Directors | Resigned | 2026-07-09 |
| Pete O’Heeron | Class III director | Appointed | 2026-06-23 |
| Jason D. Davis | Chief Financial Officer | Appointed | 2025-06-09 |
| Robert E. Hoffman | Interim Chief Financial Officer | Resigned | 2025-05-05 |
| Robert Hoffman | Interim Chief Financial Officer | Appointed | 2024-10-29 |
Leadership
- Pete O’Heeron CEO, Board Member
- Jason D. Davis CFO
- Robert Hoffman CFO
- Ruben A. Garcia General Counsel
- Kathleen Rubins Board Member
- Kathleen Rubins, Ph.D. Board Member
- Leigh Steinberg Board Member
- Pete O'Heeron Board Member
- Richard Cilento Board Member
- Robert E. Hoffman Board Member
- Stacy Coen Board Member
- Victoria Niklas Board Member